Showing 4241-4250 of 7117 results for "".
- Telehealth Webinar from Cosmetic Surgery Forum Explores Best Practiceshttps://practicaldermatology.com/news/telehealth-webinar-available-from-cosmetic-surgery-forum/2460325/As dermatologists deal with the evolving COVID-19 crisis, they are increasingly searching for guidance on the proper use of telemedicine. Joel Schlessinger, MD, Founder of Cosmetic Surgery Forum, brought together George Hruza, MD, past president of the AAD, and Antoanella Calame, MD, founder of t
- Evolve BioSystems and Janssen to Study the Impact of B. infantis EVC001 for AD Prevention in Infantshttps://practicaldermatology.com/news/evolve-biosystems-and-janssen-to-study-the-impact-of-b-infantis-evc001-for-ad-prevention-in-infants/2460324/Evolve BioSystems, Inc. and Janssen Research & Development, LLC, are partnering to conduct a study looking at the potential role of B. infantis EVC001 in preventing early childhood atopic dermatitis (AD). The study will assess the effects of introducing a specific gut
- New AAAHC COVID-19 Guidelines Call for Postponing Elective or Non-Essential Visits and Surgerieshttps://practicaldermatology.com/news/new-aaahc-covid-19-guidelines-call-for-postponing-elective-or-non-essential-visits-and-surgeries/2460323/The Accreditation Association for Ambulatory Health Care (AAAHC) is calling for the postponement of elective or non-essential visits or surgeries in their newly released guidelines. For patients that require an office visit, increas
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- 30% of Americans’ Jobs Negatively Impacted by COVID-19, Economic Fallouthttps://practicaldermatology.com/news/30-of-americans-jobs-negatively-impacted-by-covid-19-economic-fallout/2460317/While 35 percent of 1,000 Americans surveyed by LendEDU say that that their jobs have not been impacted by the Coronavirus, six percent report losing their job, 13 percent report that hours have been partially cut, and 11 percent have had hours cut entirely, though they still have their jobs.
- Nation's Largest Nurses Union to Congress: Ensure Standards for Healthcare Workers to Avoid COVID-19https://practicaldermatology.com/news/nations-largest-nurses-union-to-congress-ensure-standards-for-healthcare-workers-to-avoid-covid-19/2460314/National Nurses United, the largest union of registered nurses, is calling on Congress to mandate that the Occupational Safety and Health Administration promulgate an emergency temporary standard for health care workers in the third COVID-19 stimulus package currently being negotiated.
- Viper Equity Partners Seeks to Expand into Florida and Georgia Dermatology Marketshttps://practicaldermatology.com/news/viper-equity-partners-seeks-to-expand-into-florida-and-georgia-dermatology-markets/2460303/Viper Equity Partners is turning its attention to key dermatology and related aesthetics offices in Florida and Georgia to join private equity-backed partnerships. In an effort spearheaded by Senior Vice President Nina Das (see photo), the North Palm Beach-based M&A advisory firm is
- Study: Mohs Scars from Facial Skin Cancers Longer than Patients Expecthttps://practicaldermatology.com/news/study-mohs-scars-from-facial-skin-cancers-longer-than-patients-expect/2460301/Scars from Mohs micrographic surgery for facial skin cancers may be longer than patients expect, according to new research published in JAMA Network Open. In this cross-sectional study of 1
- Study: DermTech’s Non-Invasive Gene Expression Testing Improves Early Melanoma Detectionhttps://practicaldermatology.com/news/study-dermtechs-non-invasive-gene-expression-testing-improves-early-melanoma-detection/2460297/A large registry study confirms that DermTech Pigmented Lesion Assay can reduce unnecessary biopsies by up to 90 percent, lower healthcare costs, and rule out melanoma. “The DermTech PLA helps clinicians employ precision dermatology and harness genomics technology to detect malign
- First Patient Enrolled in Avita Medical’s Pivotal Study Evaluating Recell System for Soft Tissue Reconstructionhttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-medicals-pivotal-study-evaluating-recell-system-for-soft-tissue-reconstruction/2460294/Avita Medical Limited enrolled the first patient in a study evaluating the Recell System for Soft Tissue Reconstruction at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ. The prospective multi-center trial of at least 65 patients will compare the clinical per